European Lung Cancer Congress 2026 (ELCC 2026)

A study from Israel presented at ELCC 2026 supports the role of glucose control as a modifiable host factor that could improve the effectiveness of immune checkpoint inhibitors in the treatment of non-small cell lung cancer (NSCLC).

Data from a large, prospective, non-randomized study in China show that one-time low-dose computed tomography (LDCT) screening is associated with a significant reduction in lung cancer mortality in a non–risk-based population, including those who have never smoked.